Prostate cancer screening: and yet it moves!

Area of Science:

• Urology
• Oncology
• Preventive Medicine

Background:

• The efficacy of prostate cancer (PCa) screening remains a long-standing debate.
• Conflicting literature exists regarding the benefits and harms of prostate-specific antigen (PSA) screening.
• The European Randomized Study of Screening for Prostate Cancer (ERSPC) provides critical long-term data.

Purpose of the Study:

• To evaluate the impact of PSA screening on PCa mortality.
• To discuss the main findings from the ERSPC trials.
• To propose future directions for risk-adapted PCa screening strategies.

Main Methods:

• Analysis of long-term results from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
• Review of existing literature on PSA screening efficacy and associated harms.
• Discussion of risk-adapted screening principles.

Main Results:

• Long-term data from the ERSPC trials demonstrate a clear YES to the question of whether screening decreases PCa mortality.
• Screening benefits are associated with potential harms, necessitating careful implementation.
• The study highlights the need for a shift from past screening methods to a more targeted approach.

Conclusions:

• PSA screening effectively reduces prostate cancer mortality.
• Future screening strategies must be risk-adapted to optimize the benefit-harm balance.
• Implementing smart, targeted screening protocols is essential for effective PCa management.